ClinicalTrials.gg
Active, not recruitingNCT05531526Updated Oct 14, 2026

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

A Phase 3 interventional study of AR1001 and Placebo in Alzheimer Disease, sponsored by AriBio Co., Ltd.. Active, not recruiting at 198 sites in 13 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by AriBio Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Updated Oct 14, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,535
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
54th of 1,610
1,535 · median 73
Started
2022
with 130 others
Phase 3
188 of 1,941
19 open now
Primary completion
2026-06
later than 57 of 443 live
Registered
1,500th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 54th largest by enrollment of the 1,610 interventional ones that give a count, is one of 131 that started in 2022, is one of 188 in phase 3, reaches primary completion later than 57 of the 443 other live ones, and was the 1,500th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.

Read the detailed description

The purpose of this Study is to evaluate the efficacy and safety of AR1001 in participants with Early Alzheimer's Disease (AD).

AR1001 is a small molecule that has demonstrated its potential as a therapeutic agent for AD via its polypharmacological characteristics with multiple mechanisms to ameliorate AD pathology.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • AR1001
  • AD
  • Early AD
  • Alzheimer's disease
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 55 to 90 years of age inclusive at the time of signing the form
  2. Mild cognitive impairment or mild dementia consistent with AD defined by stages 3 to 4 according to the National Institute on Aging and Alzheimer's Association (NIA-AA) at Screening
  3. Participants with a history of subjective cognitive and memory decline with onset within 5 years before Screening, confirmed by study partner.
  4. Participants who have a score greater than or equal to 20
  5. Participants with a CDR global rating of 0.5 or 1
  6. Participants with a RBANS score based on the Delayed Memory Index (DMI) score less than or equal to 85
  7. If an historic magnetic resonance imaging (MRI) is available, findings must exclude other causes of dementia.
  8. Positive biomarker for brain amyloid pathology as indicated by assessment of at least one of the following:

    1. Current or historical CSF assessment with FDA-cleared assays, including Lumipulse® beta-amyloid ratio [1-42/1-40] ≤ 0.072, Elecsys® pTau 181/Aβ[1-42] greater than 0.023, Elecsys® tTau /Aβ[1-42] greater than 0.28, or other assays or cut-offs as they become FDA-cleared.
    2. Historical amyloid positron emission tomography (PET) assessment confirmed by the Sponsor or Designee.
  9. Participants and caregiver(s) who can sign an informed consent to participate in the study.
  10. Participants who have one (or more) identified adult study partner(s) who, in the opinion of the Investigator, has sufficient contact with and knowledge about the participant as to be able to report knowledgably about the participant's cognition, function, behavior, and safety, and compliance with the protocol. The informant/care partner must be available by phone to provide information to the Investigator and study staff about the participant as well as agree to attend in-person clinic visits that require partner input for scale completion. The informant/care partner must be able to understand the requirements of participation and provide informed consent and should be available for the duration of the study. The same informant/care partner is required to be consistent across all study visits except under rare, unavoidable circumstances (e.g., unexpected informant health crisis) that are approved by the Investigator and Sponsor.

Exclusion criteria

Exclusion Criteria:

  1. Participants who are female and are either pregnant, nursing, or of and not practicing effective
  2. Participants who have signs of significant delirium which, in the opinion of the Investigator, would interfere with this study
  3. Participants who have any diagnosis of dementia or cognitive decline other than that related to AD, including, but not limited to concomitant history of significant head trauma, alcohol abuse, frontotemporal dementia, Huntington disease, Parkinsonism (e.g., Parkinson's disease, dementia with Lewy bodies, etc.), significant cerebrovascular disease and/or significant seizure disorder
  4. Participants with any current psychiatric diagnosis if, in the judgment of the Investigator, the psychiatric disorder (e.g., schizophrenia) or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant's ability to complete the study
  5. Participants with a history of vascular dementia
  6. Participants with evidence of other neurological conditions thought to interfere with the evaluations in this study
  7. Participants with a history of myocardial infarction, unstable angina, significant coronary artery disease, and/or (NYHA) class III or IV heart failure within the last 12 months
  8. Participants with uncontrolled hypertension (systolic blood pressure (BP) >160 mmHg or diastolic BP > 95 mmHg) or hypotension (systolic BP \<90 mmHg or diastolic BP \<50 mmHg). Participants may undergo repeated testing to ensure that accurate BP readings are obtained
  9. Participants with a (BMI) ≥35 kg/m2
  10. Participants with any of the following:

    1. elevation (>2.5x [ULN]) of (aspartate aminotransferase, ALT (alanine transaminase, or total (unless known prior history of Gilbert's syndrome)
    2. deficiency (\< lower limit of normal [LLN]) of Vitamin B12
    3. known history of (human immunodeficiency virus) positivity or positive test for HIV 1/2 at screening
    4. known history of virus (HCV) or positive test for HCV antibody (HCVAb) at screening (unless negative on confirmatory PCR test)'
    5. positive test for surface antigen (HBsAg)
    6. known history of neurosyphilis or positive test for RPR at screening
  11. Participants who have history of cancer or malignant tumor within 5 years prior to screening with the exception of:

    1. Basal or squamous cell carcinoma of the skin or cervical dysplasia, which has been adequately treated
    2. In situ Grade 1 cervical cancer, fully treated at least 2 years prior to screening, and without recurrence.
    3. Prostate cancer, confined to the prostate gland, which has been adequately treated (e.g., surgery and/or radiation or watchful waiting) with normal or low and stable prostate-specific antigen (PSA) levels for 2 years prior to Screening
    4. Adequately treated non- breast cancer
  12. Participants who in the opinion of the Investigator have an inadequately treated thyroid disorder
  13. Participants with inherited degenerative retinal disease
  14. Participants who have an undiagnosed or uncontrolled seizure disorder (and/or an epileptic syndrome), which has or could lead to cognitive impairment either from repeated seizures or the medications used to control the seizure disorder
  15. Participants who are being treated, or likely to require treatment during the study, with any medications prohibited by the study protocol
  16. Participants who have participated in any drug or device trial within the previous 30 days or five half-lives of an investigational drug at Screening, whichever is longer
  17. Participants taking a cholinesterase inhibitor and/or memantine not on a stable dose for at least 3 months prior to screening. Treatment and dosing should remain stable, with no changes throughout the trial.
  18. Participants who have been and/or are currently being treated with anti-amyloid, anti-tau, or any investigational therapy for AD
  19. Participants who currently take any other PDE-5 inhibitors (e.g., sildenafil)
  20. Participants who are currently receiving (or unable to stop use for at least 14 days [2 weeks] prior to receiving the first dose of the AR1001 and throughout the study) prescription or nonprescription medications or other products known to be potent inhibitors of cytochrome P450 isozyme 3A4 ()
  21. Alcohol or substance use disorder within the past 5 years according to (DSM-5)
  22. Participants who have previously participated in a clinical trial with AR1001
  23. Participants who, in the opinion of the Investigator, are unsuitable to participate in the trial
  24. Participants who, in the opinion of the Investigator, are at significant risk of suicide.
  25. GDS-15 score ≥ 8 at Screening
  26. Participants requiring a lumbar puncture (LP) to verify amyloid pathology who have a to undergoing LP in the opinion of the Investigator. Participants requiring LP who are receiving ongoing anticoagulant therapy or antiplatelet therapy (other than aspirin and non-steroidal anti-inflammatory drugs [NSAIDs]) should also be excluded if it is considered unsafe or contraindicated to temporarily discontinue the therapy.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,535 participants (actual)

Study arms

  • Active comparator
    Group A - Active Comparator

    Active, AR1001 30 mg QD will be administered daily for 52 weeks during the Treatment Phase of the study. In the Extension Phase, all eligible participants who choose to participate will receive AR1001 30 mg QD for 52 weeks.

    Drug: AR1001

  • Placebo comparator
    Group B - Placebo Comparator

    Placebo QD will be administered daily for 52 weeks during the Treatment Phase of the study. In the Extension Phase, all eligible participants who choose to participate will receive AR1001 30 mg QD for 52 weeks.

    Drug: Placebo

Interventions

  • DrugAR1001

    AR1001 Active Oral Tablet

  • DrugPlacebo

    Placebo Oral Tablet

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) (Overall Population)

    CDR-SB is used to assess clinical decline associated with AD. The CDR is a 5-point scale used to stage AD by characterization of the 6 domains of cognitive and functional performance: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. This information is collected through a semi structured interview of the participant and the informant. Scores range from 0 to 3 (0, 0.5, 1, 2, 3), with a higher score indicating greater impairment. The CDR-SB score is obtained by summing each of the CDR domain box scores, with scores ranging from 0 to 18.

    Time frame: Baseline to Week 52

  2. Change from Baseline in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) (Monotherapy Population)

    CDR-SB is used to assess clinical decline associated with AD. The CDR is a 5-point scale used to stage AD by characterization of the 6 domains of cognitive and functional performance: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. This information is collected through a semi structured interview of the participant and the informant. Scores range from 0 to 3 (0, 0.5, 1, 2, 3), with a higher score indicating greater impairment. The CDR-SB score is obtained by summing each of the CDR domain box scores, with scores ranging from 0 to 18. The monotherapy population is a subset of the overall population that is not taking concomitant medication for AD during the trial.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change from Baseline in the Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog 13) (Overall Population)

    ADAS-Cog13 is a clinician-administered assessment of cognitive function in individuals with Alzheimer's disease that evaluates domains including memory, language, praxis, orientation, attention, and concentration. Total scores range from 0 to 85, with higher scores indicating greater cognitive impairment.

    Time frame: Baseline to Week 52

  2. Change from Baseline in the Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog 13) (Monotherapy Population)

    ADAS-Cog13 is a clinician-administered assessment of cognitive function in individuals with Alzheimer's disease that evaluates domains including memory, language, praxis, orientation, attention, and concentration. Total scores range from 0 to 85, with higher scores indicating greater cognitive impairment. The monotherapy population is a subset of the overall population that is not taking concomitant AD medication.

    Time frame: Baseline to Week 52

  3. Change from Baseline in the Amsterdam-Instrumental Activities of Daily Living Questionnaire-Short Version (A-IADL-Q-SV) (Overall Population)

    The A-IADL-Q is an adaptive and computerized questionnaire designed to assess impairments in instrumental activities of daily living (IADL) in early dementia. The questionnaire is completed by a caregiver. Higher scores indicate better everyday functioning

    Time frame: Baseline to Week 52

  4. Change from Baseline in the Amsterdam-Instrumental Activities of Daily Living Questionnaire-Short Version (A-IADL-Q-SV) (Monotherapy Population)

    The A-IADL-Q is an adaptive and computerized questionnaire designed to assess impairments in instrumental activities of daily living (IADL) in early dementia. The questionnaire is completed by a caregiver. Higher scores indicate better everyday functioning. The monotherapy population is a subset of the overall population that is not taking concomitant medication for AD during the trial.

    Time frame: Baseline to Week 52

  5. Change from Baseline in the Geriatric Depression Scale-15 (GDS-15) (Overall Population)

    The GDS-15 assesses depressive symptoms using 15 items. Scores range from 0 to 15, with higher scores indicating more depressive symptoms.

    Time frame: Baseline to Week 52

  6. Change from Baseline in the Geriatric Depression Scale-15 (GDS-15) (Monotherapy Population)

    The GDS-15 is a validated 15-item self-report questionnaire used to screen for depressive symptoms in older adults. Total scores range from 0 to 15, with higher scores indicating greater depressive symptom severity. The monotherapy population is a subset of the overall population that is not taking concomitant medication for AD during the trial.

    Time frame: Baseline to Week 52

  7. Change from Baseline in the Mini-Mental Status Examination (MMSE) (Overall Population)

    The MMSE is a clinician-administered assessment of global cognitive function that evaluates orientation, attention, memory, language, and visuospatial abilities. Total scores range from 0 to 30, with lower scores indicating greater cognitive impairment.

    Time frame: Baseline to Week 52

  8. Change from Baseline in the Mini-Mental Status Examination (MMSE) (Monotherapy Population)

    The MMSE is a clinician-administered assessment of global cognitive function that evaluates orientation, attention, memory, language, and visuospatial abilities. Total scores range from 0 to 30, with lower scores indicating greater cognitive impairment. The monotherapy population is a subset of the overall population that is not taking concomitant medication for AD during the trial.

    Time frame: Baseline to Week 52

Other outcomes

  1. Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)

    Number of participants experiencing at least one treatment-emergent adverse event (TEAE) during the safety assessment period. A TEAE is defined as an adverse event that first occurs or worsens in severity after initiation of study treatment, in accordance with the protocol-defined treatment-emergent period.

    Time frame: Up to 108 weeks

  2. Number of Participants With at Least One Treatment-Emergent Serious Adverse Event (TESAE)

    Number of participants experiencing at least one treatment-emergent serious adverse event (TESAE) during the safety assessment period. A TESAE is a serious adverse event that first occurs or worsens after initiation of study treatment, in accordance with the protocol-defined treatment-emergent period. Seriousness is determined using the criteria specified in the study protocol.

    Time frame: Up to 108 weeks

  3. Changes From Baseline in Vital Signs and Incidence of Potentially Clinically Significant Vital Sign Abnormalities

    Changes from baseline in systolic and diastolic blood pressure, pulse rate, body temperature, respiratory rate, and weight will be summarized by visit. The number and percentage of participants with potentially clinically significant treatment-emergent vital sign abnormalities will also be summarized using predefined criteria.

    Time frame: Up to 108 weeks

  4. Changes From Baseline in Electrocardiogram (ECG) Parameters and Incidence of Abnormal ECG Findings

    Changes from baseline in 12-lead ECG parameters, including heart rate, PR interval, QRS duration, QT interval, RR interval, and Fridericia-corrected QT interval (QTcF), will be summarized. The number and percentage of participants with abnormal post-baseline ECG findings, classified as clinically significant or not clinically significant, will also be summarized.

    Time frame: Up to 108 Weeks

  5. Changes From Baseline in Clinical Laboratory Parameters and Laboratory Abnormalities

    Changes from baseline in hematology, serum chemistry, coagulation, and urinalysis parameters will be summarized by visit. Laboratory abnormalities will be evaluated using laboratory reference ranges, and shifts from baseline to the maximum post-baseline Common Terminology Criteria for Adverse Events (CTCAE) grade will be summarized for hematology and chemistry parameters.

    Time frame: Up to 108 weeks

  6. Number of Participants With Suicidal Ideation, Suicidal Behavior, or Non-Suicidal Self-Injurious Behavior Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)

    The Columbia-Suicide Severity Rating Scale (C-SSRS) assesses suicidal ideation, suicidal behavior, and non-suicidal self-injurious behavior. The number and percentage of participants reporting suicidal ideation, suicidal behavior, suicidal ideation or behavior, and non-suicidal self-injurious behavior will be summarized by visit and overall. Changes in categorical responses from baseline will also be summarized for suicidal ideation and behavior. The most severe response during treatment will be used for the overall assessment.

    Time frame: Up to 108 weeks

  7. Quality of Life in Alzheimer's Disease (QoL-AD), Participant Version

    The Quality of Life in Alzheimer's Disease (QoL-AD) questionnaire assesses quality of life across 13 domains, including physical health, mood, relationships, activities, and ability to complete tasks. The participant version is completed by the study participant. Total scores range from 13 to 52, with higher scores indicating better quality of life. Change from baseline will be assessed at Weeks 52 and 104.

    Time frame: Baseline to Weeks 52 and 104

  8. Quality of Life in Alzheimer's Disease (QoL-AD), Informant Version

    The Quality of Life in Alzheimer's Disease (QoL-AD) informant questionnaire assesses the participant's quality of life across 13 domains, including physical health, mood, relationships, activities, and ability to complete tasks, as reported by an informant. Total scores range from 13 to 52, with higher scores indicating better quality of life. Change from baseline will be assessed at Weeks 52 and 104.

    Time frame: Baseline to Weeks 52 and 104

  9. Change From Baseline to Week 52 in Global Statistical Test (GST) Score

    The Global Statistical Test (GST) combines the Clinical Dementia Rating-Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13), Amsterdam-Instrumental Activities of Daily Living Questionnaire Short Version (A-IADL-Q-SV), Geriatric Depression Scale-15 (GDS-15), and Mini-Mental State Examination (MMSE) using a rank-sum percentile method. The composite score is normalized to a scale of 0 to 100, with higher scores indicating worse overall clinical status.

    Time frame: Baseline to Week 52

  10. Change From Baseline and Week 52 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) through Week 104

    The CDR-SB evaluates cognitive and functional impairment across six domains. Total scores range from 0 to 18, with higher scores indicating greater impairment. Changes from baseline and from Week 52 will be evaluated during the optional open-label Extension Phase. Participants will be analyzed by original randomized treatment group (early-start AR1001 versus delayed-start AR1001).

    Time frame: Baseline and Week 52 to Week 104

  11. Change From Baseline and Week 52 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) through Week 104

    The ADAS-Cog13 assesses cognitive performance. Total scores range from 0 to 85, with higher scores indicating greater impairment. Changes from baseline and from Week 52 will be evaluated during the optional open-label Extension Phase. Participants will be analyzed by original randomized treatment group (early-start AR1001 versus delayed-start AR1001).

    Time frame: Baseline and Week 52 to Week 104

  12. Change From Baseline and Week 52 in Amsterdam-Instrumental Activities of Daily Living Questionnaire Short Version (A-IADL-Q-SV) through Week 104

    The A-IADL-Q-SV assesses impairment in instrumental activities of daily living. Scores range from 0 to 100, with higher scores indicating worse functioning. Changes from baseline and from Week 52 will be evaluated during the optional open-label Extension Phase. Participants will be analyzed by original randomized treatment group (early-start AR1001 versus delayed-start AR1001).

    Time frame: Baseline and Week 52 to Week 104

  13. Change From Baseline and Week 52 in Geriatric Depression Scale-15 (GDS-15) through Week 104

    The GDS-15 assesses depressive symptoms using 15 items. Scores range from 0 to 15, with higher scores indicating more depressive symptoms. Changes from baseline and from Week 52 will be evaluated during the optional open-label Extension Phase. Participants will be analyzed by original randomized treatment group (early-start AR1001 versus delayed-start AR1001).

    Time frame: Baseline and Week 52 to Week 104

  14. Change From Baseline and Week 52 in Mini-Mental State Examination (MMSE) Through Week 104

    The MMSE assesses global cognitive function. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. Changes from baseline and from Week 52 will be evaluated during the optional open-label Extension Phase. Participants will be analyzed by original randomized treatment group (early-start AR1001 versus delayed-start AR1001).

    Time frame: Baseline and Week 52 to Week 104

  15. Change From Baseline in Plasma phosphorylated Tau at Threonine 217 (pTau217)

    Plasma pTau217 is a biomarker associated with Alzheimer's disease-related tau pathology. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.

    Time frame: Baseline to Weeks 52 and 104

  16. Change From Baseline in Plasma Glial Fibrillary Acidic Protein (GFAP)

    Plasma GFAP is a biomarker associated with astrocytic activation. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.

    Time frame: Baseline to Weeks 52 and 104

  17. Change From Baseline in Plasma Neurofilament Light Chain (NfL)

    Plasma NfL is a biomarker associated with neuroaxonal injury. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.

    Time frame: Baseline to Weeks 52 and 104

  18. Change From Baseline in Plasma Amyloid Beta 42 (Aβ42)

    Plasma Aβ42 is an amyloid-related biomarker. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.

    Time frame: Baseline to Weeks 52 and 104

  19. Change From Baseline in Plasma Amyloid Beta 40 (Aβ40)

    Plasma Aβ40 is an amyloid-related biomarker. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.

    Time frame: Baseline to Weeks 52 and 104

  20. Change From Baseline in Plasma amyloid beta 42 to amyloid beta 40 ratio (Aβ42/Aβ40)

    The plasma Aβ42/Aβ40 ratio is an amyloid-related biomarker calculated from the measured concentrations of Aβ42 and Aβ40. Changes from baseline to Week 52 and during the optional Extension Phase through Week 104 will be evaluated. Changes from Week 52 during the Extension Phase will also be summarized.

    Time frame: Baseline to Weeks 52 and 104

  21. Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Cyclic Guanosine Monophosphate (cGMP)

    cGMP a signaling molecule associated with the nitric oxide/cGMP pathway. Change from baseline to Week 52 in CSF cGMP will be evaluated to assess the effect of AR1001 compared with placebo.

    Time frame: Baseline to Week 52

  22. Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Cyclic Adenosine Monophosphate (cAMP)

    cAMP is an intracellular signaling molecule. Change from baseline to Week 52 in CSF cAMP will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.

    Time frame: Baseline to Week 52

  23. Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) phosphorylated Tau at Threonine 217 (pTau217)

    pTau217 is a biomarker associated with Alzheimer's disease-related tau pathology. Change from baseline to Week 52 in CSF pTau217 will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.

    Time frame: Baseline to Week 52

  24. Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Glial Fibrillary Acidic Protein (GFAP)

    GFAP is a biomarker associated with astrocytic activation. Change from baseline to Week 52 in CSF GFAP will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.

    Time frame: Baseline to Week 52

  25. Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Amyloid Beta 42 (Aβ42)

    Aβ42 is an amyloid-related biomarker. Change from baseline to Week 52 in CSF Aβ42 will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.

    Time frame: Baseline to Week 52

  26. Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Amyloid Beta 40 (Aβ40)

    Aβ40 is an amyloid-related biomarker. Change from baseline to Week 52 in CSF Aβ40 will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.

    Time frame: Baseline to Week 52

  27. Change From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Amyloid Beta 42 to Amyloid Beta 40 ratio (Aβ42/Aβ40)

    Aβ42/Aβ40 ratio is an amyloid-related biomarker calculated from measured CSF Aβ42 and Aβ40 concentrations. Change from baseline to Week 52 in CSF Aβ42/Aβ40 will be evaluated to assess the effect of AR1001 compared with placebo during the Treatment Phase.

    Time frame: Baseline to Week 52

  28. Change From Baseline to Week 52 in Volumetric MRI

    Change from baseline to Week 52 in whole brain volume and brain region (i.e, hippocamus) volumes will be assessed using volumetric magnetic resonance imaging (MRI).

    Time frame: Baseline to Week 52

  29. Plasma Concentrations of AR1001 for Population Pharmacokinetic Analysis

    Plasma concentrations of AR1001 will be measured to characterize the single-dose and multiple-dose population pharmacokinetic profile. Samples will be collected pre-dose and at 30, 60, and 120 minutes postdose at Weeks 0, 26, and 52.

    Time frame: Weeks 0, 26, and 52

  30. Plasma Concentrations of M14 for Population Pharmacokinetic Analysis

    Plasma concentrations of M14 will be measured to characterize the single-dose and multiple-dose population pharmacokinetic profile. Samples will be collected pre-dose and at 30, 60, and 120 minutes postdose at Weeks 0, 26, and 52.

    Time frame: Weeks 0, 26, and 52

07

Study locations

198 sites

Showing the first 100 of 198 sites across 13 countries. Choose a country and city above to see the rest.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jun 2026, 42 months.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 42 months is close to that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion May 2026 → Jun 2026 and completion Dec 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2022
First posted
Sep 8, 2022
StartActual
Dec 23, 2022
Primary completionActual
Jun 29, 2026was May 2026
CompletionEst.
Oct 2027was Dec 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 2026→Jun 29, 2026 (actual)
Oct 14, 2026
Study completion
Dec 2027→Oct 2027
Oct 14, 2026
Eligibility
2 inclusion criteria edited; 9 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipants (or participant's legally authorized representative) and caregiver (s) who can sign an informed consent to participate in the study.
  • EditedParticipants who have one (or more) identified adult study partners partner(s) who, in the opinion of the Investigator, has sufficient contact with and knowledge about the participant as to be able to report knowledgably about the participant's cognition, function, behavior, and safety, and compliance with the protocol. The informant/care partner must be available by phone to provide information to the Investigator and study staff about the participant as well as agree to attend in-person clinic visits that require partner input for scale completion. The informant/care partner must be literateable to understand the requirements of participation and provide informed consent and should be available for the duration of the study. The same informant/care partner is required to be consistent across all study visits except under rare, unavoidable circumstances (e.g., unexpected informant health crisis) that are approved by the Investigator and Sponsor.
Exclusion criteria
  • EditedParticipants who have any diagnosis of dementia or cognitive decline other than that related to AD, including, but not limited to concomitant history of significant head trauma, alcohol abuse, frontotemporal dementia, Huntington Diseasedisease, Parkinsonism (e.g., Parkinson's disease, Dementiadementia with Lewy Bodiesbodies, etc.), significant cerebrovascular disease, and/or significant seizure disorder
  • EditedParticipants with a history of myocardial infarction, unstable angina, significant coronary artery disease, and/or New York Heart Association (NYHA) class III or IV heart failure within the last 12 months
  • EditedParticipants with a body mass index (BMI) > ≥35 kg/m2
  • EditedParticipants taking an orala cholinesterase inhibitor and/or memantine not on a stable dose for at least 3 months prior to screening. Treatment and dosing should remain stable, with no changes throughout the trial.
  • EditedParticipants who have been and/or are currently being treated with anti-amyloid, anti-tau, or any other investigational therapiestherapy for AD
  • EditedParticipants who, in the opinion of the Investigator, who are unsuitable to participate in the trial
  • EditedParticipants who, in the opinion of the Investigator, are at significant risk of suicide.
  • EditedGDS-15 score greater than equal to≥ 8 at Screening
  • EditedParticipants, requiring a lumbar puncture (LP) to verify amyloid pathology who have a contraindication to undergoing LP in the opinion of the Investigator,. Participants requiring LP who have any who have any contraindications to undergoing LP. Participantsare receiving ongoing anticoagulant therapy or antiplatelet therapy (other than aspirin and non-steroidal anti-inflammatory drugs [NSAIDs]) should also be excluded if it is considered unsafe or contraindicated to temporarily discontinue the therapy.
Oct 14, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedChange from Baseline in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) (Overall Population)Time frame: 52 weeks → Baseline to Week 52
  • AddedChange from Baseline in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) (Monotherapy Population)Time frame: Baseline to Week 52
Oct 14, 2026
Secondary outcomes
4 edited, 26 added, 11 more
What changed in the outcomes
  • EditedChange from Baseline in the Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog 13) (Overall Population)Time frame: 52 weeks → Baseline to Week 52
  • EditedChange from Baseline in the Amsterdam-Instrumental Activities of Daily Living Questionnaire-Short Version (A-IADL-Q-SV) (Overall Population)Time frame: 52 weeks → Baseline to Week 52
  • EditedChange from Baseline in the Geriatric Depression Scale-15 (GDS-15) (Overall Population)Time frame: 52 weeks → Baseline to Week 52
  • EditedChange from Baseline in the Mini-Mental Status Examination (MMSE) (Overall Population)Time frame: 52 weeks → Baseline to Week 52
  • AddedChange from Baseline in the Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog 13) (Monotherapy Population)Time frame: Baseline to Week 52
  • AddedChange from Baseline in the Amsterdam-Instrumental Activities of Daily Living Questionnaire-Short Version (A-IADL-Q-SV) (Monotherapy Population)Time frame: Baseline to Week 52
  • AddedChange from Baseline in the Geriatric Depression Scale-15 (GDS-15) (Monotherapy Population)Time frame: Baseline to Week 52
  • AddedChange from Baseline in the Mini-Mental Status Examination (MMSE) (Monotherapy Population)Time frame: Baseline to Week 52
  • Addedother outcomeNumber of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: Up to 108 weeks
  • Addedother outcomeNumber of Participants With at Least One Treatment-Emergent Serious Adverse Event (TESAE)Time frame: Up to 108 weeks
  • Addedother outcomeChanges From Baseline in Vital Signs and Incidence of Potentially Clinically Significant Vital Sign AbnormalitiesTime frame: Up to 108 weeks
  • Addedother outcomeChanges From Baseline in Electrocardiogram (ECG) Parameters and Incidence of Abnormal ECG FindingsTime frame: Up to 108 Weeks
  • Addedother outcomeChanges From Baseline in Clinical Laboratory Parameters and Laboratory AbnormalitiesTime frame: Up to 108 weeks
  • Addedother outcomeNumber of Participants With Suicidal Ideation, Suicidal Behavior, or Non-Suicidal Self-Injurious Behavior Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 108 weeks
  • Addedother outcomeQuality of Life in Alzheimer's Disease (QoL-AD), Participant VersionTime frame: Baseline to Weeks 52 and 104
  • Addedother outcomeQuality of Life in Alzheimer's Disease (QoL-AD), Informant VersionTime frame: Baseline to Weeks 52 and 104
  • Addedother outcomeChange From Baseline to Week 52 in Global Statistical Test (GST) ScoreTime frame: Baseline to Week 52
  • Addedother outcomeChange From Baseline and Week 52 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) through Week 104Time frame: Baseline and Week 52 to Week 104
  • Addedother outcomeChange From Baseline and Week 52 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) through Week 104Time frame: Baseline and Week 52 to Week 104
  • Addedother outcomeChange From Baseline and Week 52 in Amsterdam-Instrumental Activities of Daily Living Questionnaire Short Version (A-IADL-Q-SV) through Week 104Time frame: Baseline and Week 52 to Week 104
  • Addedother outcomeChange From Baseline and Week 52 in Geriatric Depression Scale-15 (GDS-15) through Week 104Time frame: Baseline and Week 52 to Week 104
  • Addedother outcomeChange From Baseline and Week 52 in Mini-Mental State Examination (MMSE) Through Week 104Time frame: Baseline and Week 52 to Week 104
  • Addedother outcomeChange From Baseline in Plasma phosphorylated Tau at Threonine 217 (pTau217)Time frame: Baseline to Weeks 52 and 104
  • Addedother outcomeChange From Baseline in Plasma Glial Fibrillary Acidic Protein (GFAP)Time frame: Baseline to Weeks 52 and 104
  • Addedother outcomeChange From Baseline in Plasma Neurofilament Light Chain (NfL)Time frame: Baseline to Weeks 52 and 104
  • Addedother outcomeChange From Baseline in Plasma Amyloid Beta 42 (Aβ42)Time frame: Baseline to Weeks 52 and 104
  • Addedother outcomeChange From Baseline in Plasma Amyloid Beta 40 (Aβ40)Time frame: Baseline to Weeks 52 and 104
  • Addedother outcomeChange From Baseline in Plasma amyloid beta 42 to amyloid beta 40 ratio (Aβ42/Aβ40)Time frame: Baseline to Weeks 52 and 104
  • Addedother outcomeChange From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Cyclic Guanosine Monophosphate (cGMP)Time frame: Baseline to Week 52
  • Addedother outcomeChange From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Cyclic Adenosine Monophosphate (cAMP)Time frame: Baseline to Week 52
  • …and 11 more, on the record history on ClinicalTrials.gov ↗
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion May 2026→Jun 29, 2026 (now actual)
    Study completion Dec 2027→Oct 2027
    Eligibility 2 inclusion criteria edited; 9 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants (or participant's legally authorized representative) and caregiver (s) who can sign an informed consent to participate in the study.
    • EditedParticipants who have one (or more) identified adult study partners partner(s) who, in the opinion of the Investigator, has sufficient contact with and knowledge about the participant as to be able to report knowledgably about the participant's cognition, function, behavior, and safety, and compliance with the protocol. The informant/care partner must be available by phone to provide information to the Investigator and study staff about the participant as well as agree to attend in-person clinic visits that require partner input for scale completion. The informant/care partner must be literateable to understand the requirements of participation and provide informed consent and should be available for the duration of the study. The same informant/care partner is required to be consistent across all study visits except under rare, unavoidable circumstances (e.g., unexpected informant health crisis) that are approved by the Investigator and Sponsor.
    Exclusion criteria
    • EditedParticipants who have any diagnosis of dementia or cognitive decline other than that related to AD, including, but not limited to concomitant history of significant head trauma, alcohol abuse, frontotemporal dementia, Huntington Diseasedisease, Parkinsonism (e.g., Parkinson's disease, Dementiadementia with Lewy Bodiesbodies, etc.), significant cerebrovascular disease, and/or significant seizure disorder
    • EditedParticipants with a history of myocardial infarction, unstable angina, significant coronary artery disease, and/or New York Heart Association (NYHA) class III or IV heart failure within the last 12 months
    • EditedParticipants with a body mass index (BMI) > ≥35 kg/m2
    • EditedParticipants taking an orala cholinesterase inhibitor and/or memantine not on a stable dose for at least 3 months prior to screening. Treatment and dosing should remain stable, with no changes throughout the trial.
    • EditedParticipants who have been and/or are currently being treated with anti-amyloid, anti-tau, or any other investigational therapiestherapy for AD
    • EditedParticipants who, in the opinion of the Investigator, who are unsuitable to participate in the trial
    • EditedParticipants who, in the opinion of the Investigator, are at significant risk of suicide.
    • EditedGDS-15 score greater than equal to≥ 8 at Screening
    • EditedParticipants, requiring a lumbar puncture (LP) to verify amyloid pathology who have a contraindication to undergoing LP in the opinion of the Investigator,. Participants requiring LP who have any who have any contraindications to undergoing LP. Participantsare receiving ongoing anticoagulant therapy or antiplatelet therapy (other than aspirin and non-steroidal anti-inflammatory drugs [NSAIDs]) should also be excluded if it is considered unsafe or contraindicated to temporarily discontinue the therapy.
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedChange from Baseline in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) (Overall Population)Time frame: 52 weeks → Baseline to Week 52
    • AddedChange from Baseline in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) (Monotherapy Population)Time frame: Baseline to Week 52
    Secondary outcomes 4 edited, 26 added, 11 more
    What changed in the outcomes
    • EditedChange from Baseline in the Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog 13) (Overall Population)Time frame: 52 weeks → Baseline to Week 52
    • EditedChange from Baseline in the Amsterdam-Instrumental Activities of Daily Living Questionnaire-Short Version (A-IADL-Q-SV) (Overall Population)Time frame: 52 weeks → Baseline to Week 52
    • EditedChange from Baseline in the Geriatric Depression Scale-15 (GDS-15) (Overall Population)Time frame: 52 weeks → Baseline to Week 52
    • EditedChange from Baseline in the Mini-Mental Status Examination (MMSE) (Overall Population)Time frame: 52 weeks → Baseline to Week 52
    • AddedChange from Baseline in the Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog 13) (Monotherapy Population)Time frame: Baseline to Week 52
    • AddedChange from Baseline in the Amsterdam-Instrumental Activities of Daily Living Questionnaire-Short Version (A-IADL-Q-SV) (Monotherapy Population)Time frame: Baseline to Week 52
    • AddedChange from Baseline in the Geriatric Depression Scale-15 (GDS-15) (Monotherapy Population)Time frame: Baseline to Week 52
    • AddedChange from Baseline in the Mini-Mental Status Examination (MMSE) (Monotherapy Population)Time frame: Baseline to Week 52
    • Addedother outcomeNumber of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: Up to 108 weeks
    • Addedother outcomeNumber of Participants With at Least One Treatment-Emergent Serious Adverse Event (TESAE)Time frame: Up to 108 weeks
    • Addedother outcomeChanges From Baseline in Vital Signs and Incidence of Potentially Clinically Significant Vital Sign AbnormalitiesTime frame: Up to 108 weeks
    • Addedother outcomeChanges From Baseline in Electrocardiogram (ECG) Parameters and Incidence of Abnormal ECG FindingsTime frame: Up to 108 Weeks
    • Addedother outcomeChanges From Baseline in Clinical Laboratory Parameters and Laboratory AbnormalitiesTime frame: Up to 108 weeks
    • Addedother outcomeNumber of Participants With Suicidal Ideation, Suicidal Behavior, or Non-Suicidal Self-Injurious Behavior Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 108 weeks
    • Addedother outcomeQuality of Life in Alzheimer's Disease (QoL-AD), Participant VersionTime frame: Baseline to Weeks 52 and 104
    • Addedother outcomeQuality of Life in Alzheimer's Disease (QoL-AD), Informant VersionTime frame: Baseline to Weeks 52 and 104
    • Addedother outcomeChange From Baseline to Week 52 in Global Statistical Test (GST) ScoreTime frame: Baseline to Week 52
    • Addedother outcomeChange From Baseline and Week 52 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) through Week 104Time frame: Baseline and Week 52 to Week 104
    • Addedother outcomeChange From Baseline and Week 52 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) through Week 104Time frame: Baseline and Week 52 to Week 104
    • Addedother outcomeChange From Baseline and Week 52 in Amsterdam-Instrumental Activities of Daily Living Questionnaire Short Version (A-IADL-Q-SV) through Week 104Time frame: Baseline and Week 52 to Week 104
    • Addedother outcomeChange From Baseline and Week 52 in Geriatric Depression Scale-15 (GDS-15) through Week 104Time frame: Baseline and Week 52 to Week 104
    • Addedother outcomeChange From Baseline and Week 52 in Mini-Mental State Examination (MMSE) Through Week 104Time frame: Baseline and Week 52 to Week 104
    • Addedother outcomeChange From Baseline in Plasma phosphorylated Tau at Threonine 217 (pTau217)Time frame: Baseline to Weeks 52 and 104
    • Addedother outcomeChange From Baseline in Plasma Glial Fibrillary Acidic Protein (GFAP)Time frame: Baseline to Weeks 52 and 104
    • Addedother outcomeChange From Baseline in Plasma Neurofilament Light Chain (NfL)Time frame: Baseline to Weeks 52 and 104
    • Addedother outcomeChange From Baseline in Plasma Amyloid Beta 42 (Aβ42)Time frame: Baseline to Weeks 52 and 104
    • Addedother outcomeChange From Baseline in Plasma Amyloid Beta 40 (Aβ40)Time frame: Baseline to Weeks 52 and 104
    • Addedother outcomeChange From Baseline in Plasma amyloid beta 42 to amyloid beta 40 ratio (Aβ42/Aβ40)Time frame: Baseline to Weeks 52 and 104
    • Addedother outcomeChange From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Cyclic Guanosine Monophosphate (cGMP)Time frame: Baseline to Week 52
    • Addedother outcomeChange From Baseline to Week 52 in Cerebrospinal Fluid (CSF) Cyclic Adenosine Monophosphate (cAMP)Time frame: Baseline to Week 52
    • …and 11 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: verification date, oversight details and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05531526
Lead sponsor
AriBio Co., Ltd.
Responsible party
Sponsor
First posted
Sep 8, 2022
Start date
Dec 23, 2022
Primary completion
Jun 29, 2026
Completion
Oct 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

James Rock
study director · AriBio Co., Ltd.
Sharon Sha, MD, MS
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion